front 1 Blood enters the glomerulus via the____ arteriole, and leaves via the____ | back 1 afferent, efferent |
front 2 Excess ethanol consumption can lead to liver steatosis. Explain what liver steatosis is and how ethanol consumption can lead to steatosis | back 2 Certainly! Let’s dive into the role of NADH in metabolic processes, particularly its significance in ethanol breakdown and the regulation of fat synthesis and breakdown.
Remember, NADH is like a cellular currency, shuttling electrons and participating in vital reactions. Understanding its role helps us appreciate the intricate dance of metabolism! |
front 3 A given drugs has a total clearance value (CL) of 3 L/hr and a volume of distribution (Vd) of 20 L, what is the elimination rate constant (Kel)? | back 3 3/20 |
front 4 Asprin (structure below) has a pKa of 3.5. Is it more likely to cross cell membranes in your stomach or in your intestines? Why? | back 4 Aspirin is a weak acid with a pKa of 3.5. When aspirin is ingested it is more likely to be absorbed in the stomach then intestine. The stomach pH is acidic (1.5-3.5) and at this state aspirin is in its non-ionization form causing it to be more lipophilic and diffuse more readily across the cell membrane. |
front 5 Binding to a plasma protein might _______ toxicity and _______ half-life. | back 5 decrease; increase |
front 6 Nitroglycerin is a drug that is used to treat angina (chest pain). When administered orally, it has poor bioavailability and thus it is typically administered sublingually (under the tongue). What is bioavailability and how might this route administration affect the bioavailability of nitroglycerin? | back 6 Bioavailability describes the proportion of a substance that is absorbed into the blood, and drugs that are ingested may have lower bioavailability due to the first-pass effect. If nitroglycerin is delivered sublingually it bypasses first-pass metabolism. |
front 7 Explain why it is dangerous to take NSAIDS and ACE-inhibitors at the same time. | back 7 Certainly! Let’s delve into the intricate details of how NSAIDs (nonsteroidal anti-inflammatory drugs) and ACE inhibitors impact renal function, specifically focusing on the efferent and afferent arterioles.
Remember, the kidneys are intricate organs, and maintaining their delicate balance is essential for overall health. |
front 8 Toxicology | back 8 Is the study of the adverse effects of chemical on living organisms is the branch of science concerned with the nature effects and detection of poisons |
front 9 Ebers Papyrus | back 9 oldest medical toxicologist documented |
front 10 20th century is | back 10 where toxicology become a real thing |
front 11 Paracelsus | back 11 made important improvements on dosages |
front 12 Ebers Papyrus | back 12 One of the oldest known writings (1500 B.C.) Contains information on many recognized poisons |
front 13 Bioavailability | back 13
|
front 14 Overdose | back 14 An overdose occurs when you take more than the recommended amount of something, often a medicine or drug. It can result in serious, harmful symptoms or even death. If you intentionally take too much of something, it is called an intentional or deliberate overdose 1. In simpler terms, it’s like going beyond the safety limit and facing potentially severe consequences. |
front 15 De Materia Medica | back 15 first book to talk about plant reproduction and plant poisons |
front 16 Bioavailability | back 16 How much is actively poisoning you |
front 17 Rapidity of the toxic response | back 17 onset of action |
front 18 The effectiveness of the compound | back 18 potency |
front 19 The degree of response of the parts of the body | back 19 specificity site of action |
front 20 Complaints of victims | back 20 clinical signs and symptoms |
front 21 Paracelsus | back 21 Dose makes the poison published on the miners sickness and other disease of miners |
front 22 Absorption | back 22
|
front 23 Distribution | back 23
|
front 24 first scientific journal dedicated to toxicology | back 24 Archiv Fur Toxikologie |
front 25 Mechanism of toxicology | back 25 identifies the cellular, biochemical, and molecular |
front 26 Descriptive toxicology: | back 26 direct toxicity testing which provides information for |
front 27 Regulatory toxicology: | back 27 deciding if (based on mechanistic and descriptive |
front 28 • Forensic toxicology | back 28 focuses on the medicolegal aspects of the harmful effects |
front 29 Clinical toxicology: | back 29 study of diseases caused by or uniquely associated with toxic |
front 30 Environmental toxicology: | back 30 focuses on the impacts of chemical pollutants in the
|
front 31 Developmental toxicology | back 31 the study of how exposure to chemicals before |
front 32 Reproductive toxicology: | back 32 the study of what happens to the male or female |
front 33 Toxicogenomics: | back 33 looks at the interaction between genes and toxicants in toxicity etiology |
front 34 Transcriptomics | back 34 gene expression |
front 35 Proteomics | back 35 protein expression |
front 36 Metabolomics | back 36 small molecule metabolism and functions |
front 37 Potential questions asked in toxicogenomics | back 37 How does a chemical affect genomic DNA, mRNA, or other RNAs? |
front 38 Poison | back 38 any agent capable of producing a deleterious response in a biological |
front 39 Toxic agents can be classified by their | back 39 physical state, chemical stability or |
front 40 Toxin | back 40 toxic substances produced by biological systems |
front 41 Toxicants | back 41 toxic substances that are a product of human activities |
front 42 Lethal dose 50: LD50 | back 42 The dose needed to produce death in 50% of |
front 43 Side effects that are always deleterious to humans are referred to | back 43 adverse, deleterious, or toxic effects of the drugs |
front 44 • Chemical allergens: | back 44 an adverse immune response to a chemical (usually due to
|
front 45 Chemical idiosyncrasy: | back 45 genetically related abnormal reactivity to a chemical |
front 46 Delayed toxicity: | back 46 most toxic effects occur rapidly after a single administration of
|
front 47 Site of action: | back 47 Local (place of initial contact) vs systemic toxicity. Target organs |
front 48 Tolerance | back 48 prior exposure = decreased responsiveness to a toxic effect |
front 49 Additive | back 49 2+2=4 |
front 50 Synergistic | back 50 combined effect of chemicals is much greater 2+2=20 |
front 51 Potentiation | back 51 0+2=10 one chemical doesn't do anything but can if something is mixed within it Example: Isopropanol and carbon tetrachloride |
front 52 Functional Antagonism | back 52 counter balance. opposite effects. 4+(-4) = 0 |
front 53 Chemical antagonism | back 53 Chemical reaction between two toxins that produce a less toxic effect |
front 54 Dispositional antagonism | back 54 About how interference with absorption happens. Biotransformation. distribution. excretion |
front 55 Receptor antagonism | back 55 Two chemicals bind at the same receptor chemical binds receptor |
front 56 Major routes of exposure | back 56 Gastrointestinal tract (ingestion) |
front 57 Acute | back 57 Usually single administration (or within 24 hours |
front 58 Subacute | back 58 repeated exposure for 1 month or less |
front 59 Subchronic | back 59 repeated exposure for 1-3 months |
front 60 Chronic | back 60 more than 3 months |
front 61 What does line A represent? | back 61 a chemical with very slow |
front 62 What does line B represent? | back 62 A chemical with a rate of |
front 63 What does line C represent? | back 63 Rate of elimination faster than its |
front 64 What does the purple shading mean | back 64 the concentration of the |
front 65 Individual refers to | back 65 an individual organism |
front 66 Quantal refers to | back 66 a population of organisms |
front 67 • Individual dose-response relationship: | back 67 which describes the response of an individual organism to
|
front 68 Quantal dose-response relationships: | back 68 all or none |
front 69 Effective dose (ED) is a | back 69 statistical |
front 70 | back 70 similar ED 50 btu could have different dosage effects overall (range of error) |
front 71 Assumptions in deriving the dose-response relationship | back 71 The response is due to the administered chemical (cause-and-effect
|
front 72 TD | back 72 Toxic dose |
front 73 LD | back 73 Lethal dose |
front 74 ED | back 74 Effective dose |
front 75 Therapeutic index (TI): | back 75 ratio of the dose for a toxic effect and dose needed to elicit a
TI =TD50/ED50 ED50 = 50% response level of the effective dose TD50= toxic dose is 50% of population |
front 76 Chemical A is _______ potent than B | back 76 More and more |
front 77 Maximal Efficacy | back 77 Chemicals A and B = same Chemicals C and D = c has a lower maximal efficiency then d |
front 78 Selective toxicity | back 78 a chemical produces injury to one kind of living |
front 79 • A lot of toxicity studies rely of experimental results being | back 79 applicable to humans, BUT responses can have qualitative and quantitative differences |
front 80 Acute toxicity testing: | back 80 Daily examination of animals→ could watch for signs of
LD50 determined using 1+ routes of exposure and 1+ species
|
front 81 Subacute | back 81 monitoring effects of repeated doses, typically over a period of 14
|
front 82 Subchronic | back 82 Usually lasts at least 90 days. One of the main goals is to establish the lowest observed adverse effect (LOAEL) or the no observed adverse effect (NOAEL) |
front 83 Chronic | back 83 6 months- 2 years, done similarly to subchronic tests. One of the main goals is often to evaluate potential oncogenicity |
front 84 idiosyncratic reactions, | back 84
|
front 85 reversible vs irreversible toxic effects | back 85
|
front 86 local vs systemic effects | back 86
|
front 87 LD50 | back 87
|
front 88 ED50 | back 88
|
front 89 potency | back 89
|
front 90 maximal efficacy | back 90
|
front 91 • Differentiate between individual and quantal dose-response relationships and understand their graphical representation | back 91 Certainly! Let’s explore the differences between individual dose-response relationships and quantal dose-response relationships, along with their graphical representations:
In summary, individual dose-response relationships focus on an individual’s graded response, while quantal dose-response relationships analyze binary outcomes in a population. Both provide valuable insights for drug dosing and safety considerations. |
front 92 Ultimate toxicant | back 92 could be original chemical or |
front 93 Absorption | back 93 the transfer of a chemical from the site of exposure into the
|
front 94 Factors that influence absorption: | back 94 Surface area of exposure |
front 95 Presystemic elimination: | back 95 during transfer to systemic circulation |
front 96 •Distribution: | back 96 exit blood and reach site(s) of action |
front 97 Mechanism facilitating distribution to a target | back 97 Porosity of the capillary endothelium |
front 98 • Mechanisms opposing distribution to a target | back 98 • Specialized barriers |
front 99 Excretion | back 99 removal of the xenobiotic from the blood |
front 100 Reabsorption | back 100 Toxic chemicals are filtered and then reenter into the blood
|
front 101 Biotransformation | back 101 the biochemical modification of a chemical compound |
front 102 Toxication (or metabolic activation): | back 102 Biotransformation to harmful products |
front 103 Detoxication | back 103 biotransformation that eliminate the toxicant |
front 104 Most common targets: | back 104 nucleic acids (especially DNA), proteins, and membranes |
front 105 The toxicant reacts with the target and adversely affects its
function | back 105 non covalent, covalent interactions, hydrogen abstraction, redox reactions, enzymatic reactions |
front 106 The toxicant reaches effective concentrations at the | back 106 target site |
front 107 The toxicant alters the target in a way that is mechanistically | back 107 related to observed toxicity |
front 108 Molecular repair | back 108 Repairing proteins (molecular chaperones, other enzymes, or mark for
degradation if beyond repair) |
front 109 Cellular repair | back 109 • Autophagy→ removing and degrading damaged cellular components like
organelles |
front 110 Tissue repair | back 110 Apoptosis and regeneration (replacement of cells and extracellular matrix) |
front 111 Adaptation | back 111 A harm-induced capability |
front 112 Examples of toxicity resulting from inappropriate repair and | back 112 Tissue necrosis (tissue cell death—injury overwhelms/disables repair
|
front 113 Delivery | back 113 Delivery in relation to toxicology encompasses several critical aspects. Let’s explore them:
In summary, toxicology plays a vital role in delivering justice, safeguarding public health, and understanding the impact of toxic substances on individuals and the environment. |
front 114 Toxicokinetics | back 114 the quantitative study of absorption, distribution, |
front 115 Some factors that affect the rate of absorption | back 115 How easily a toxic substance can cross a membrane (lipophilic? Uses a
transporter? Ionized [pH |
front 116 Facilitated diffusion: | back 116 down the |
front 117 Active transport | back 117 against a gradient, selective |
front 118 Most toxicants cross membranes by | back 118 simple diffusion |
front 119 Getting to the brain | back 119 Must cross the blood brain barrier |
front 120 Placental barrier | back 120 Numerous cell layers (~6) between fetal and maternal circulations
that have different |
front 121 Route of exposure and absorption | back 121 Gastrointestinal tract |
front 122 How is Absorption measured? | back 122 • Level of chemicals in blood, urine, tissues |
front 123 Distribution | back 123 (going from the bloodstream throughout the body) |
front 124 Volume of distribution (Vd): | back 124 the apparent volume of a biological fluid the |
front 125 Storage sites include: | back 125 liver, kidney, fat, bone, and plasma protein |
front 126 Distribution and plasma proteins as a storage depot | back 126 Some xenobiotics bind to plasma |
front 127 Elimination | back 127 Excretion |
front 128 Toxicokinetics | back 128 the quantitative study of absorption, distribution, |
front 129 If F < 1 then | back 129 then less than 100% of the administered dose reaches systemic |
front 130 Most toxic substances aren’t delivered intravenously, and Bioavailability (F) describes | back 130 the extent of absorption (or the proportion of toxicant that enters |
front 131 Volume of Distribution (Vd): | back 131 the apparent volume of a biological fluid the |
front 132 Clearance (CL): | back 132 the apparent volume of physiological fluid that is cleaned of a
|
front 133 The elimination rate constant (Kel) represents | back 133 the fraction of the amount of a 10 L/Hr /100 L = 0.1 per hour |
front 134 Because the percent of elimination over a given period of time is constant, it is more common to refer to an | back 134 elimination half-life (t1/2): the time it takes for the concentration
Cl= 10 Vd = 100 (0.693 * 100 )/10 = 6.93 hours |
front 135 Toxicokinetics | back 135 the quantitative study of absorption, distribution, |
front 136 Classic model: | back 136 chemicals move through the body as if there were |
front 137 Physiologic toxicokinetic models: | back 137 attempt to portray the body as an elaborate system of discrete tissue or organ compartments that are interconnected via circulatory system |
front 138 Know how plasma proteins affect xenobiotic distribution | back 138 Certainly! Let’s explore how plasma proteins impact the distribution of xenobiotics (foreign substances, such as drugs or toxins) within the body:
In summary, plasma proteins play a crucial role in determining the distribution of xenobiotics, affecting their availability to target tissues and potential toxic effects. |
front 139 Distinguish between classic and physiologic toxicokinetic models | back 139 Certainly! Let’s delve into the differences between classic and physiologically based toxicokinetic (PBTK) models:
In summary, classic models are simpler but lack physiological detail, while PBTK models offer a more comprehensive understanding of toxicokinetics by incorporating anatomical and physiological complexities1 2 3 4. |
front 140 The liver is the main organ facilitating | back 140 metabolic homeostasis |
front 141 The liver is the main organ where | back 141 exogenous chemicals are |
front 142 Dual blood supply: Heaptic artery from: hepatic portal vein from: | back 142 Heart: (supplies oxygen rich stomach and |
front 143 Steatosis | back 143 Fatty liver→ increased lipid content in liver cells |
front 144 Fibrosis | back 144 scaring when chronic liver injury overwhelms the capacity of the organ to repair |
front 145 Liver cancers come from | back 145 chronic abuse of alcohol, androgens, and aflatoxin-contaminated diets |
front 146 Some of the functions of the kidney | back 146 Filter blood and produce urine |
front 147 Why are kidneys susceptible to toxicity? | back 147 Kidneys receive 20-25% of cardiac |
front 148 how does blood flow trough the Glomerulus | back 148 • Blood enters via the afferent arteriole |
front 149 egulating factors of | back 149 Angiotensin II: vasoconstrictor effect on |
front 150 Example of kidney toxicity: NSAIDS | back 150 Nonsteroidal Anti-Inflammatory |
front 151 Example of kidney toxicity: ACE-Inhibitors | back 151 Angiotensin-converting enzyme (ACE)-inhibitors: medications that
|
front 152 Taking NSAIDS and ACE-inhibitors at the | back 152 nephrotoxicity |
front 153 Toxic responses of the reproductive system include any adverse
effects on sexual Example: | back 153 Expose adult animals whatever chemical for 2 weeks prior to breeding: 1) are they ovulating normally 2) is the same amount of sperm being 3) How many embryos implanted 4) How many are giving birth |
front 154 Toxic responses of the brain: cyanide | back 154 • cyanide binds and inhibits |
front 155 cyanide inhibits what in the brain | back 155 cytochrome C, and thus ATP synthesis |
front 156 More than 90% of a dose of ethanol is metabolized in the liver | back 156 liver steatosis → liver fibrosis → liver cirrhosis |
front 157 neoplasia | back 157 new growth or autonomous growth of tissue |
front 158 Neoplasm | back 158 The lesion resulting from neoplasia |
front 159 Benign | back 159 Lesion characterized by expansive growth, frequently exhibiting slow rates of proliferation they do not invade surrounding areas |
front 160 Malignant | back 160 Lesions demonstrating invasive growth, capable of metastasis to other tissues or organs |
front 161 metastases | back 161 Secondary growths derived from a primary malignant neoplasm |
front 162 Tumor | back 162 Lesion characterized by swelling or increasing in size, may or may not be neoplastic |
front 163 Cancer | back 163 Malignant neoplam |
front 164 Carcinogen | back 164 A physical or chemical agent that causes or induces neoplasia |
front 165 Genotoxic | back 165 Carcinogens that interact with DNA resulting in mutation |
front 166 Non-genotoxic | back 166 Carcinogens that modify gene expression but do not damage DNA |
front 167 Carcinogen | back 167 A physical or chemical agent that causes or induces neoplasia |
front 168 Direct acting carcinogens: | back 168 highly reactive |
front 169 Indirect acting carcinogens | back 169 : (more common) |
front 170 The ultimate carcinogenic forms are | back 170 frequently strong electrophiles (nucleophiles |
front 171 Chemicals containing these moieties frequently cause | back 171 tumor formation at the site of chemical exposure |
front 172 Mismatch repair | back 172 mechanism to repair point mutations |
front 173 Excision repair: | back 173 mechanism to repair DNA regions containing |
front 174 Homologous recombination and nonhomologous end-joining: | back 174 mechanism to repair double stranded breaks |
front 175 oncogene | back 175 a gene that is capable of transformation cells in a |
front 176 Proto-oncogenes | back 176 are genes that regulate cell proliferation, growth, and differentiation, and control the cell cycle. |
front 177 Tumor-suppressor genes | back 177 are genes that inhibit cell proliferation or cell survival |
front 178 Examples of non-genotoxic carcinogens Receptor mediated: | back 178 example phenobarbital |
front 179 Examples of non-genotoxic carcinogens Hormonal mode of action: | back 179 example estrogen |
front 180 Examples of non-genotoxic carcinogens Immunosuppression | back 180 cancer immune surveillance is |
front 181 Connect genotoxic carcinogens with the development of cancer | back 181 Certainly! Let’s delve into the connection between genotoxic carcinogens and the development of cancer.
In summary, genotoxic carcinogens play a pivotal role in cancer development by damaging DNA and initiating abnormal cell growth. Researchers continue to explore these mechanisms to improve cancer prevention and treatment strategies. |
front 182 Distinguish between direct and indirect acting carcinogens and understand that genotoxic carcinogens are typically electrophiles | back 182 Certainly! Let’s explore the differences between direct-acting and indirect-acting carcinogens, as well as the role of genotoxic carcinogens as electrophiles:
In summary, direct-acting carcinogens directly interact with cellular components, while indirect-acting carcinogens require metabolic activation. Genotoxic carcinogens, often electrophiles, play a critical role in initiating DNA damage and promoting cancer progression. Understanding these distinctions helps in cancer prevention and risk assessment. |
front 183 basic understanding of the stages of carcinogenesis | back 183 Certainly! Let’s explore the stages of carcinogenesis, which describe the process by which normal cells transform into cancerous cells:
In summary, carcinogenesis is a complex process involving initiation, promotion, progression, malignant transformation, and metastasis. Understanding these stages helps in cancer prevention, early detection, and targeted therapies. |
front 184 Routes of administration | back 184 oral, IV, inhalation |
front 185 Common types of target molecules for toxic chemicals | back 185 Nucleic acids (DNA) proteins membranes |
front 186 Different types of disrepair | back 186 tissue necrosis: tissue cell death, injury overwhelms/ disables repair mechanisms Fibrosis: extracellular matrix deposition with abnormal composition Carcinogenesis: failure to repair DNA, Failure to apoptosis failure to terminate cell proliferation |
front 187 How ionization affects crossing cell membrane | back 187 un-ionized form of a drug is usually lipid soluble and can readily cross the cell membrane ionized = low lipid solubility and cant cross the cell membrane when pH is = to pKa then un-ionized drug = 50:50 or in other words pKa is the pH where drug is 50% ionized and passes membranes |
front 188 Genotoxic | back 188 carcinogens that interact with DNA resulting in mutation indirect = require biotransformation; not directly binding to DNA direct = directly interacting with DNA causing direct damage |
front 189 non-genotoxic | back 189 carcinogens that modify gene expression but don't damage DNA |
front 190 Stages of carcinogens | back 190 1) Initiation: Damage DNA then initiate cell (= potential cancer) 2) promotion: stimulate growth, no DNA damage in this step 3) progression: initiated cells accumulate additional genetic alterations |
front 191 interesting history fact | back 191 Catherin de Medici (1519-1589): tested toxic concentrations on subjects, took note of how rapid they were intoxicated, their degree of response, the effectiveness of the toxin, ect. |
front 192 Quantal dose curves | back 192 all or none. An individual in a population of organisms is classified as either a responder or a non-responder. Shows % of responders at different dosages. CAan show ED50 |
front 193 Individual dose curves | back 193 focused on graded response of an individual to varying dosages of a drug. Continues relationships. Represent effect of different doses on individual, measured on a grade scale such as blood pressure, pain relief, enzyme activity. X axis = dose y axis = graded response |
front 194 How ethanol consumption can lead to liver steatosis | back 194 Primary pathway for ethanol breakdown is through ADH (alcohol dehydrogenase) ADH oxidizes NADH to NAD+ while reducing acetaldehyde to ethanol. NADH leads to steatosis by signaling a down regulation of fatty acid breakdown and up regulating fatty acid synthesis. |
front 195 The route of blood flow through the glomerulus and describe the effect of NSAIDS and ACE-inhibitors on that flow | back 195 The blood flow through the glomerulus first goes through afferent arteriole then will get filtered and goes out the efferent arteriole. NSAIDs will cause constriction of afferent arteriole causing increased blood pressure in the glomerulus (stops production of prostaglandins). ACE inhibitors block conversion of angiotensin 1 to angiotensin 2 which inhibits efferent arteriolar vasoconstriction. If taken together no blood flow to the glomerulus will occur going either in or out causes kidneys to die. |
front 196 How the route of exposure impacts bioavailability (IV and oral) | back 196 Route of exposure impacts bioavailability due to the process it has to go through specially the filtration process. When it is ingested orally it must go through the intestinal tract that absorbs and filters before putting things into the blood stream. This bioavailability is much less in comparison to IV because when administered intravenously it goes directly into the blood without a filtering process first which could take some of the medication or toxin out first so essentially the bioavailability in IV is 100% and the oral way of consumption's bioavailability would be less then 100% |
front 197 Fun fact about batrachotoxin | back 197 found in birds, frogs, beetles binds irreversible to the sodium channels in the body leaving them open no known antidote at this time indigenous people have used frogs with poison on darts to hunt it was discovered in 1963 Takashi T. solved the steroidal structure using x-ray diffraction |